Nectar Lifesciences quarterly results and financials

Nectar Lifesciences (NECLIFE)₹10.25−0.29%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Nectar Lifesciences reported sales of ₹0 Cr, down 100.0% from Jun 2025, and net profit of −₹14.98 Cr. For the year to Mar 2026, sales were ₹0 Cr and net profit −₹293 Cr.

Sales (Jun 2026): ₹0 Cr
Net profit (Jun 2026): −₹14.98 Cr
Sales (FY Mar 2026): ₹0 Cr
Net profit (FY Mar 2026): −₹293 Cr
EPS (Jun 2026): ₹−0.78
Borrowings (Mar 2026): ₹0 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Nectar Lifesciences quarterly results

₹ crore unless stated; each column is a quarter.

Nectar Lifesciences Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	397	450	439	358	5.98	0.00	0.00	4.98	0.99	0.00	0.99	0.00
Expenses	371	410	393	319	5.99	0.00	0.00	5.99	0.00	2.01	58.99	27.99
Operating Profit	27.06	42.11	48.09	40.12	−1.01	0.00	0.00	−1.01	1.01	−2.01	−57.12	−27.06
OPM %	7.0%	8.9%	10.9%	10.9%	−10.0%	−500.1%	−500.1%	−16.1%	76.9%	—	−4,437.1%	−6,198.1%
Other Income	10.99	0.00	0.99	0.99	7.01	8.01	−130	−61.95	−176	34.97	−23.99	3.01
Interest	20.94	24.94	23.92	19.95	0.00	0.00	0.00	0.00	0.00	29.92	5.98	0.00
Depreciation	15.04	15.05	15.06	15.05	0.00	0.00	0.00	1.01	0.00	0.00	0.00	0.00
Profit before tax	2.01	2.01	11.01	5.01	4.99	8.01	−130	−64.01	−176	3.01	−87.92	−24.02
Tax %	38.1%	36.1%	95.1%	40.1%	−2.0%	2.0%	0.0%	−1.0%	0.0%	−339.0%	−21.9%	−36.9%
Exceptional items	0.00	0.00	0.00	0.00	6.01	7.99	−130	−62.97	−176	34.98	−30.99	0.00
Net Profit	0.99	1.99	0.99	2.99	5.99	7.99	−130	−62.97	−176	13.98	−67.94	−14.98
EPS (Rs)	0.04	0.06	0.02	0.12	0.24	0.34	−5.79	−2.81	−7.84	0.63	−3.49	−0.78

Nectar Lifesciences profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Nectar Lifesciences Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1,667	1,629	1,867	2,769	2,356	1,535	1,660	1,515	1,675	1,659	0.00	1.98
Expenses	1,435	1,411	1,637	2,516	2,143	1,431	1,506	1,467	1,531	1,695	7.99	88.99
Operating Profit	240	224	237	265	221	109	159	53.11	152	−30.07	−8.02	−85.18
OPM %	13.9%	13.9%	13.0%	9.9%	8.9%	7.0%	10.0%	3.5%	8.9%	−1.8%	−2,920.1%	−4,302.0%
Other Income	5.99	22.98	5.99	6.01	3.99	−21.98	10.99	42.98	14.99	4.99	−279	−162
Interest	123	117	115	148	126	112	78.76	78.75	86.72	74.83	35.90	35.90
Depreciation	57.20	62.17	64.17	63.16	61.15	60.20	57.20	59.18	61.23	62.20	0.00	0.00
Profit before tax	63.96	67.04	62.99	58.99	36.99	−85.02	33.98	−42.02	18.01	−162	−323	−285
Tax %	15.1%	18.1%	17.1%	19.1%	15.1%	−13.9%	26.1%	−43.0%	73.1%	−29.9%	−8.9%	—
Exceptional items	0.00	1.01	0.00	0.00	0.00	−25.01	7.01	41.03	0.00	0.00	−51.98	−172
Net Profit	53.93	54.96	51.99	47.94	31.97	−72.91	24.99	−23.96	4.99	−114	−293	−245
EPS (Rs)	2.41	2.46	2.32	2.11	1.41	−3.26	1.11	−1.07	0.21	−5.06	−15.04	−11.48
Dividend payout %	4.0%	2.0%	2.0%	2.0%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Nectar Lifesciences balance sheet

₹ crore, at each year end.

Nectar Lifesciences Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	22.01	21.99	22.01	21.99	22.02	22.02	22.02	22.00	21.99	22.01	22.01	18.97
Reserves	938	934	986	1,038	1,085	1,117	1,043	1,067	1,045	1,049	936	563
Borrowings	925	962	878	955	903	778	903	860	754	635	582	0.00
Other Liabilities	628	640	694	708	694	717	421	441	369	484	507	38.81
Total Liabilities	2,512	2,558	2,581	2,725	2,705	2,634	2,389	2,391	2,190	2,190	2,047	622
Fixed Assets	937	908	884	854	827	787	774	725	663	644	634	105
CWIP	91.01	99.08	102	100	100	115	99.01	85.01	78.01	66.05	57.05	0.00
Investments	0.99	1.01	0.99	0.99	0.99	0.00	0.99	0.99	0.99	0.99	0.99	12.98
Other Assets	1,484	1,551	1,595	1,770	1,778	1,732	1,515	1,580	1,448	1,480	1,355	503
Inventories	792	839	857	861	919	980	589	661	674	710	692	0.00
Trade receivables	448	493	502	615	561	398	377	449	281	380	347	0.00
Cash & equivalents	33.10	37.12	13.04	9.04	21.09	21.06	26.11	18.07	18.06	20.06	19.05	112
Total Assets	2,512	2,558	2,581	2,725	2,705	2,634	2,389	2,391	2,190	2,190	2,047	622

Nectar Lifesciences cash flow

₹ crore, for each year.

Nectar Lifesciences Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	144	169	199	64.98	239	285	20.99	94.88	134	225	169	−348
Cash from investing activity	−59.99	−76.93	−17.99	−28.98	−25.99	−32.97	−29.01	16.98	51.94	−16.99	−42.01	1,208
Cash from financing activity	−60.81	−88.70	−203	−39.87	−200	−251	10.97	−119	−185	−204	−128	−765
Net cash flow	23.08	3.01	−23.05	−4.01	12.03	0.00	4.01	−8.03	0.00	2.01	−1.01	93.29
Capex	79.76	81.77	52.91	32.92	37.90	54.90	30.95	24.94	29.94	28.93	43.90	11.98
Free cash flow	63.81	86.74	174	31.90	203	248	−9.97	110	182	194	126	−340
CFO / OP %	56.0%	74.0%	92.1%	33.1%	96.0%	134.1%	23.1%	60.0%	252.0%	148.0%	−574.0%	4,132.1%

Nectar Lifesciences ratios

Working-capital days and returns, by year.

Nectar Lifesciences Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	98	106	111	118	72	60	88	97	66	81	75	—
Inventory days	254	261	271	227	152	193	186	198	213	216	185	—
Days payable	147	155	168	143	81	105	109	113	101	128	118	—
Cash conversion cycle	208	214	216	204	146	151	167	183	180	171	144	—
Working capital days	40	41	45	67	46	53	6	73	77	63	43	—
ROCE %	11.0%	10.0%	10.0%	9.0%	10.0%	8.0%	3.0%	5.0%	0.0%	6.0%	−5.0%	0.0%

Nectar Lifesciences: frequently asked questions

What are the latest quarterly results of Nectar Lifesciences?

For the Jun 2026 quarter, Nectar Lifesciences reported sales of ₹0 Cr, down 100.0% year on year and net profit of −₹14.98 Cr. The operating margin was −6,198.1%.

What is the annual revenue of Nectar Lifesciences?

Nectar Lifesciences' sales for the year to Mar 2026 were ₹0 Cr; over the last twelve months they were ₹1.98 Cr.

What is the net profit of Nectar Lifesciences?

Net profit for the year to Mar 2026 was −₹293 Cr, and −₹245 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−11.48.

How much debt does Nectar Lifesciences have?

Nectar Lifesciences reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹112 Cr.

What is the free cash flow of Nectar Lifesciences?

Cash from operations was −₹348 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹340 Cr.

Loading…